CHRISTIE BALLANTYNE to Cost-Benefit Analysis
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Cost-Benefit Analysis.
Connection Strength
0.326
-
Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Netw Open. 2022 02 01; 5(2):e2148172.
Score: 0.162
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.132
-
Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med. 1998 Oct 12; 158(18):1977-89.
Score: 0.032